Transgenic animal models in toxicology: historical perspectives and future outlook.

Transgenic animal models are powerful tools for developing a more detailed understanding on the roles of specific genes in biological pathways and systems. Applications of these models have been made within the field of toxicology, most notably for the screening of mutagenic and carcinogenic potential and for the characterization of toxic mechanisms of action. It has long been a goal of research toxicologists to use the data from these models to refine hazard identification and characterization to better inform human health risk assessments. This review provides an overview on the applications of transgenic animal models in the assessment of mutagenicity and carcinogenicity, their use as reporter systems, and as tools for understanding the roles of xenobiotic-metabolizing enzymes and biological receptors in the etiology of chemical toxicity. Perspectives are also shared on the future outlook for these models in toxicology and risk assessment and how transgenic technologies are likely to be an integral tool for toxicity testing in the 21st century.

[1]  J. Short,et al.  Analysis of spontaneous and induced mutations in transgenic mice using a lambda ZAP/lacl shuttle vector , 1991, Environmental and molecular mutagenesis.

[2]  A. Moschetta,et al.  Master regulation of bile acid and xenobiotic metabolism via the FXR, PXR and CAR trio. , 2009, Frontiers in bioscience.

[3]  K A McAllister,et al.  Mammary Tumor Induction and Premature Ovarian Failure in ApcMin Mice Are Not Enhanced by Brca2 Defi ciency , 2001, Toxicologic pathology.

[4]  K. Morimura,et al.  Peroxisome Proliferator-Activated Receptor α Regulates a MicroRNA-Mediated Signaling Cascade Responsible for Hepatocellular Proliferation , 2007, Molecular and Cellular Biology.

[5]  C. Bradfield,et al.  The Aryl Hydrocarbon Receptor sans Xenobiotics: Endogenous Function in Genetic Model Systems , 2007, Molecular Pharmacology.

[6]  F. Gonzalez,et al.  Pregnane X receptor‐ and CYP3A4‐humanized mouse models and their applications , 2011, British journal of pharmacology.

[7]  Timothy M Willson,et al.  The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. , 2002, Endocrine reviews.

[8]  J. Vijg,et al.  Transgenic mouse models for studying mutations in vivo: applications in aging research , 1997, Mechanisms of Ageing and Development.

[9]  C. Elcombe,et al.  The coordinate regulation of DNA synthesis and suppression of apoptosis is differentially regulated by the liver growth agents, phenobarbital and methylclofenapate. , 1998, Carcinogenesis.

[10]  A. Jaiswal,et al.  Disruption of the DT Diaphorase (NQO1) Gene in Mice Leads to Increased Menadione Toxicity* , 1998, The Journal of Biological Chemistry.

[11]  Thomas Hartung,et al.  Are in vitro tests suitable for regulatory use? , 2009, Toxicological sciences : an official journal of the Society of Toxicology.

[12]  U. Pitkänen,et al.  Liver size and indices of drug metabolism in alcoholics , 1978, European Journal of Clinical Pharmacology.

[13]  T. Pineau,et al.  Immune system impairment and hepatic fibrosis in mice lacking the dioxin-binding Ah receptor , 1995, Science.

[14]  L. Moore,et al.  Functional and structural comparison of PXR and CAR. , 2003, Biochimica et biophysica acta.

[16]  R. Tennant,et al.  Follicular origin of epidermal papillomas in v-Ha-ras transgenic TG.AC mouse skin. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[17]  E. Candido,et al.  Transgenic Caenorhabditis elegans strains as biosensors. , 1996, Trends in biotechnology.

[18]  Philippe Soriano Generalized lacZ expression with the ROSA26 Cre reporter strain , 1999, Nature Genetics.

[19]  D. Zalko,et al.  A CASCADE of effects of bisphenol A. , 2009, Reproductive toxicology.

[20]  Markus Reischl,et al.  Zebrafish embryos as models for embryotoxic and teratological effects of chemicals. , 2009, Reproductive toxicology.

[21]  R. Roberts,et al.  Species differences in response to peroxisome proliferators correlate in vitro with induction of DNA synthesis rather than suppression of apoptosis. , 1996, Carcinogenesis.

[22]  F. Gonzalez,et al.  Potential role for human cytochrome P450 3A4 in estradiol homeostasis. , 2005, Endocrinology.

[23]  F. Bunz,et al.  ATM and ATR: Components of an Integrated Circuit , 2007, Cell cycle.

[24]  J. Gustafsson,et al.  Aryl hydrocarbon receptor-mediated signal transduction. , 1997, Critical reviews in toxicology.

[25]  D. Nebert,et al.  Toward the evaluation of function in genetic variability: Characterizing human SNP frequencies and establishing BAC‐transgenic mice carrying the human CYP1A1_CYP1A2 locus , 2005, Human mutation.

[26]  L. Donehower,et al.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.

[27]  Takahiro Ochiya,et al.  Generation of genetically modified rats from embryonic stem cells , 2010, Proceedings of the National Academy of Sciences.

[28]  R. Tennant,et al.  Review Article: Use of Transgenic Animals for Carcinogenicity Testing: Considerations and Implications for Risk Assessment , 2000 .

[29]  A. Walker,et al.  The toxicology of dieldrin (HEOD). II. Comparative long-term oral toxicity studies in mice with dieldrin, DDT, phenobarbitone, -BHC and -BHC. , 1973, Food and cosmetics toxicology.

[30]  R. de Kanter,et al.  Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction , 2006, Expert opinion on drug metabolism & toxicology.

[31]  D. Nebert,et al.  Oral Benzo[a]pyrene in Cyp1 Knockout Mouse Lines: CYP1A1 Important in Detoxication, CYP1B1 Metabolism Required for Immune Damage Independent of Total-Body Burden and Clearance Rate , 2006, Molecular Pharmacology.

[32]  C. Wolf,et al.  Human constitutive androstane receptor (CAR) and pregnane X receptor (PXR) support the hypertrophic but not the hyperplastic response to the murine nongenotoxic hepatocarcinogens phenobarbital and chlordane in vivo. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.

[33]  G. Perdew,et al.  Ligand Selectivity and Gene Regulation by the Human Aryl Hydrocarbon Receptor in Transgenic Mice , 2009, Molecular Pharmacology.

[34]  A. Børresen Oncogenesis in ovarian cancer , 1992, Acta obstetricia et gynecologica Scandinavica. Supplement.

[35]  D E Robinson,et al.  Background and Framework for ILSI's Collaborative Evaluation Program on Alternative Models for Carcinogenicity Assessment , 2001, Toxicologic pathology.

[36]  M. P. Carty,et al.  DNA polymerase eta, a key protein in translesion synthesis in human cells. , 2010, Sub-cellular biochemistry.

[37]  J M Ward,et al.  Protection against acetaminophen toxicity in CYP1A2 and CYP2E1 double-null mice. , 1998, Toxicology and applied pharmacology.

[38]  T. Pineau,et al.  Role of CYP 2 E 1 in the Hepatotoxicity of Acetaminophen * , 1996 .

[39]  B. Allen,et al.  Analysis of in vivo mutation data can inform cancer risk assessment. , 2008, Regulatory toxicology and pharmacology : RTP.

[40]  T. Nohmi,et al.  Heavy‐ion‐induced mutations in the gpt delta transgenic mouse: Effect of p53 gene knockout , 2002, Environmental and molecular mutagenesis.

[41]  T. Nohmi,et al.  Novel transgenic rat for in vivo genotoxicity assays using 6‐thioguanine and Spi− selection , 2003, Environmental and molecular mutagenesis.

[42]  M. Waterman,et al.  Alterations in the regulation of androgen-sensitive Cyp 4a monooxygenases cause hypertension , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[43]  A. Maggi,et al.  In vivo imaging of transcriptionally active estrogen receptors , 2003, Nature Medicine.

[44]  G. Riou Proto-oncogenes and prognosis in early carcinoma of the uterine cervix. , 1988, Cancer surveys.

[45]  H. Aburatani,et al.  Mmh/Ogg1 gene inactivation results in accumulation of 8-hydroxyguanine in mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[46]  F. Gonzalez,et al.  PPARalpha: mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators. , 2008, Toxicology.

[47]  U. Pitkänen,et al.  Hepatic blood flow and drug metabolism in patients on enzyme-inducing anticonvulsants , 2004, European Journal of Clinical Pharmacology.

[48]  J. Idle,et al.  A Double Transgenic Mouse Model Expressing Human Pregnane X Receptor and Cytochrome P450 3A4 , 2008, Drug Metabolism and Disposition.

[49]  Ai-Ming Yu,et al.  THE CYP2E1-HUMANIZED TRANSGENIC MOUSE: ROLE OF CYP2E1 IN ACETAMINOPHEN HEPATOTOXICITY , 2005, Drug Metabolism and Disposition.

[50]  J. Vijg,et al.  Bacteriophage Lambda and Plasmid lacZ Transgenic Mice for Studying Mutations in Vivo , 1996 .

[51]  L. Donehower,et al.  Loss of p53 in benzene-induced thymic lymphomas in p53+/- mice: evidence of chromosomal recombination. , 2000, Cancer research.

[52]  G. Perdew,et al.  Regulation of Gene Expression , 2008, Goodman's Medical Cell Biology.

[53]  J. French,et al.  Analysis of genetic instability during mammary tumor progression using a novel selection-based assay for in vivo mutations in a bacteriophage lambda transgene target. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[54]  D. Nebert,et al.  Oral exposure to benzo[a]pyrene in the mouse: detoxication by inducible cytochrome P450 is more important than metabolic activation. , 2004, Molecular pharmacology.

[55]  J. Foster Cell Death and Cell Proliferation in the Control of Normal and Neoplastic Tissue Growth , 2000, Toxicologic pathology.

[56]  A. Maggi,et al.  Molecular imaging, an innovative methodology for whole-body profiling of endocrine disrupter action. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[57]  R. Roberts,et al.  The perturbation of apoptosis and mitosis by drugs and xenobiotics. , 1999, Pharmacology & therapeutics.

[58]  B. Neuschwander‐Tetri,et al.  Humanized xenobiotic response in mice expressing nuclear receptor SXR , 2000, Nature.

[59]  Robert Kavlock,et al.  The U.S. Environmental Protection Agency Strategic Plan for Evaluating the Toxicity of Chemicals , 2010, Journal of toxicology and environmental health. Part B, Critical reviews.

[60]  J. Abraham The international conference on harmonisation of technical requirements for registration of pharmaceuticals for human use , 2009 .

[61]  M. Ingelman-Sundberg,et al.  Generation of Mice Transgenic for Human CYP2C18 and CYP2C19: Characterization of the Sexually Dimorphic Gene and Enzyme Expression , 2008, Drug Metabolism and Disposition.

[62]  G. Perdew,et al.  Differential gene regulation by the human and mouse aryl hydrocarbon receptor. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.

[63]  E Spencer Williams,et al.  The transgenic mouse assay as an alternative test method for regulatory carcinogenicity studies--implications for REACH. , 2009, Regulatory toxicology and pharmacology : RTP.

[64]  K. Kinzler,et al.  The multistep nature of cancer. , 1993, Trends in genetics : TIG.

[65]  Alan R. Boobis,et al.  IPCS Framework for Analyzing the Relevance of a Noncancer Mode of Action for Humans , 2008, Critical reviews in toxicology.

[66]  A. Poso,et al.  Amino Acids Important for Ligand Specificity of the Human Constitutive Androstane Receptor* , 2005, Journal of Biological Chemistry.

[67]  H. Greim,et al.  CYP1B1 determines susceptibility to low doses of 7,12-dimethylbenz[a]anthracene-induced ovarian cancers in mice: correlation of CYP1B1-mediated DNA adducts with carcinogenicity. , 2003, Carcinogenesis.

[68]  C. Wolf,et al.  A novel panel of mouse models to evaluate the role of human pregnane X receptor and constitutive androstane receptor in drug response. , 2008, The Journal of clinical investigation.

[69]  M. Cimino,et al.  An evaluation of the mode of action framework for mutagenic carcinogens case study: Cyclophosphamide , 2008, Environmental and molecular mutagenesis.

[70]  Vicki L Dellarco,et al.  Mode of action in relevance of rodent liver tumors to human cancer risk. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.

[71]  A. Bauer,et al.  Use of genetically modified mouse models to assess pathways of benzene-induced bone marrow cytotoxicity and genotoxicity. , 2005, Chemico-biological interactions.

[72]  A. Look,et al.  Cell transformation by ras and regulation of its protein product. , 1993, Ciba Foundation symposium.

[73]  R. Caprioli,et al.  The Anti-tumorigenic Properties of Peroxisomal Proliferator-activated Receptor α Are Arachidonic Acid Epoxygenase-mediated* , 2010, The Journal of Biological Chemistry.

[74]  J. Idle,et al.  The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse. , 2001, Molecular pharmacology.

[75]  J Vijg,et al.  Plasmid rescue from transgenic mouse DNA using LacI repressor protein conjugated to magnetic beads. , 1993, BioTechniques.

[76]  P. Apostoli,et al.  Isomer-specific activity of dichlorodyphenyltrichloroethane with estrogen receptor in adult and suckling estrogen reporter mice. , 2002, Endocrinology.

[77]  R. Mittelstaedt,et al.  Induction of 6‐thioguanine‐resistant lymphocytes in fischer 344 rats following in vivo exposure to n‐ethyl‐n‐nitrosourea and cyclophosphamide , 1991, Environmental and molecular mutagenesis.

[78]  James E Klaunig,et al.  The Human Relevance of Information on Carcinogenic Modes of Action: Overview , 2003, Critical reviews in toxicology.

[79]  Ignacio Anegon,et al.  Knockout Rats via Embryo Microinjection of Zinc-Finger Nucleases , 2009, Science.

[80]  F. Gonzalez,et al.  Targeted Disruption of the Microsomal Epoxide Hydrolase Gene , 1999, The Journal of Biological Chemistry.

[81]  T. Jacks,et al.  Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer development. , 2005, Cancer research.

[82]  H. van Steeg,et al.  Transgenic and knockout mice for DNA repair functions in carcinogenesis and mutagenesis. , 2003, Toxicology.

[83]  C. Tohyama,et al.  Distinct response to dioxin in an arylhydrocarbon receptor (AHR)-humanized mouse , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[84]  J. Idle,et al.  Rifampicin-Activated Human Pregnane X Receptor and CYP3A4 Induction Enhance Acetaminophen-Induced Toxicity , 2009, Drug Metabolism and Disposition.

[85]  R. Tukey,et al.  Tissue-specific, Inducible, and Hormonal Control of the Human UDP-Glucuronosyltransferase-1 (UGT1) Locus* , 2005, Journal of Biological Chemistry.

[86]  P. Slijepcevic The role of DNA damage response proteins at telomeres--an "integrative" model. , 2006, DNA repair.

[87]  Riou Gf Proto-oncogenes and prognosis in early carcinoma of the uterine cervix. , 1988 .

[88]  M. Veldhoen,et al.  The aryl hydrocarbon receptor: fine-tuning the immune-response. , 2010, Current opinion in immunology.

[89]  T. Willson,et al.  The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[90]  Ai-Ming Yu,et al.  Drug-metabolizing enzyme, transporter, and nuclear receptor genetically modified mouse models , 2011, Drug metabolism reviews.

[91]  D. Hanahan,et al.  Transgenic mice as probes into complex systems. , 1989, Science.

[92]  C. Esser,et al.  The aryl hydrocarbon receptor (AHR), a novel regulator of human melanogenesis , 2010, Pigment cell & melanoma research.

[93]  N. Gorelick,et al.  Prospects for safety testing: A strategy for the application of transgenic rodent mutagenesis assays , 1996, Environmental and molecular mutagenesis.

[94]  Hiroshi Suzuki,et al.  Parp-1 deficiency causes an increase of deletion mutations and insertions/rearrangements in vivo after treatment with an alkylating agent , 2005, Oncogene.

[95]  J. Vijg,et al.  Spontaneous and X-ray-induced deletion mutations in a LacZ plasmid-based transgenic mouse model. , 1995, Mutation research.

[96]  G. Douglas,et al.  Cytogenetic mapping of λgt10 lacZ sequences in the transgenic mouse strain 40.6 (MutaTMMouse) , 1995 .

[97]  F. Gonzalez The 2006 Bernard B . Brodie Award Lecture CYP 2 E 1 , 2006 .

[98]  R. Edwards,et al.  Growth Hormone Determines Sexual Dimorphism of Hepatic Cytochrome P450 3A4 Expression in Transgenic Mice , 2006, Journal of Pharmacology and Experimental Therapeutics.

[99]  E. Seeberg,et al.  Accumulation of premutagenic DNA lesions in mice defective in removal of oxidative base damage. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[100]  J. Olsen,et al.  Cancer among epileptic patients exposed to anticonvulsant drugs. , 1989, Journal of the National Cancer Institute.

[101]  F. Gonzalez,et al.  Targeted Disruption of Soluble Epoxide Hydrolase Reveals a Role in Blood Pressure Regulation* , 2000, The Journal of Biological Chemistry.

[102]  Mario R. Capecchi,et al.  Gene targeting in mice: functional analysis of the mammalian genome for the twenty-first century , 2005, Nature Reviews Genetics.

[103]  J. Olsen,et al.  Antiepileptic treatment and risk for hepatobiliary cancer and malignant lymphoma. , 1995, Cancer research.

[104]  J. Ward,et al.  Differential susceptibility of mice humanized for peroxisome proliferator-activated receptor alpha to Wy-14,643-induced liver tumorigenesis. , 2006, Carcinogenesis.

[105]  J. Corton,et al.  Reduction of benzene metabolism and toxicity in mice that lack CYP2E1 expression. , 1996, Toxicology and applied pharmacology.

[106]  J. Heideman Transgenic rats: a discussion. , 1991, Biotechnology.

[107]  G. Perdew,et al.  Transgenic Humanized AHR Mouse Reveals Differences between Human and Mouse AHR Ligand Selectivity. , 2009, Molecular and cellular pharmacology.

[108]  J. Idle,et al.  The Pregnane X Receptor Gene-Humanized Mouse: A Model for Investigating Drug-Drug Interactions Mediated by Cytochromes P450 3A , 2007, Drug Metabolism and Disposition.

[109]  T. Pineau,et al.  Role of CYP2E1 in the Hepatotoxicity of Acetaminophen (*) , 1996, The Journal of Biological Chemistry.

[110]  Lung-Ji Chang,et al.  Efficient generation of transgenic rats through the male germline using lentiviral transduction and transplantation of spermatogonial stem cells. , 2006, Journal of andrology.

[111]  F. Gonzalez,et al.  Transgenic models in xenobiotic metabolism and toxicology. , 2002, Toxicology.

[112]  G. Douglas,et al.  Treatment and sampling protocols for transgenic mutation assays , 2003, Environmental and molecular mutagenesis.

[113]  F. Gonzalez CYP2E1 , 2006, Drug Metabolism and Disposition.

[114]  B. Stockinger Beyond toxicity: aryl hydrocarbon receptor-mediated functions in the immune system , 2009, Journal of biology.

[115]  G. Williams,et al.  Phenobarbital mechanistic data and risk assessment: enzyme induction, enhanced cell proliferation, and tumor promotion. , 1996, Pharmacology & therapeutics.

[116]  J. Short,et al.  The use of shuttle vectors for mutation analysis in transgenic mice and rats. , 1994, Mutation research.

[117]  S. Hussain,et al.  p53 Tumor Suppressor Gene: At the Crossroads of Molecular Carcinogenesis, Molecular Epidemiology, and Human Risk Assessment , 2000, Annals of the New York Academy of Sciences.

[118]  D C Wight,et al.  Transgenic mice: a decade of progress in technology and research. , 1994, Mutation research.

[119]  D. Smith,et al.  Ten nucleotide differences, five of which cause amino acid changes, are associated with the Ah receptor locus polymorphism of C57BL/6 and DBA/2 mice. , 1993, Pharmacogenetics.

[120]  Y Fujii-Kuriyama,et al.  Dioxin binding activities of polymorphic forms of mouse and human arylhydrocarbon receptors. , 1994, The Journal of biological chemistry.

[121]  N. Henderson,et al.  Site-specific DNA recombination in mammalian cells by the Cre recombinase of bacteriophage P1. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[122]  Jae Young Lee,et al.  Structure and Mechanism of Human DNA Polymerase η , 2010, Nature.

[123]  D. Nebert,et al.  Generation of 'humanized' hCYP1A1_1A2_Cyp1a1/1a2(-/-) mouse line. , 2007, Biochemical and biophysical research communications.

[124]  M Younes,et al.  IPCS conceptual framework for evaluating a mode of action for chemical carcinogenesis. , 2001, Regulatory toxicology and pharmacology : RTP.

[125]  R. Palmiter,et al.  Metallothionein-human GH fusion genes stimulate growth of mice. , 1983, Science.

[126]  J. Sedivy,et al.  Analysis of biological selections for high-efficiency gene targeting , 1995, Molecular and cellular biology.

[127]  D. Moore,et al.  Modulation of Acetaminophen-Induced Hepatotoxicity by the Xenobiotic Receptor CAR , 2002, Science.

[128]  L. Moore,et al.  Orphan Nuclear Receptors Constitutive Androstane Receptor and Pregnane X Receptor Share Xenobiotic and Steroid Ligands* , 2000, The Journal of Biological Chemistry.

[129]  Carolyn Vickers,et al.  IPCS framework for analysing the relevance of a cancer mode of action for humans , 2006 .

[130]  F. Gonzalez,et al.  The PPARα-Humanized Mouse: A Model to Investigate Species Differences in Liver Toxicity Mediated by PPARα , 2008 .

[131]  Jiunn H. Lin,et al.  CYP Induction-Mediated Drug Interactions: in Vitro Assessment and Clinical Implications , 2006, Pharmaceutical Research.

[132]  J. Vijg,et al.  Background mutations and polymorphisms in lacZ‐plasmid transgenic mice , 1999, Environmental and molecular mutagenesis.

[133]  J. Ward,et al.  Diminished Hepatocellular Proliferation in Mice Humanized for the Nuclear Receptor Peroxisome Proliferator-Activated Receptor α , 2004, Cancer Research.

[134]  E. Sandgren,et al.  Cell‐specific transgene expression from a widely transcribed promoter using Cre/lox in mice , 2002, Genesis.

[135]  C. Harris,et al.  Molecular epidemiology and carcinogenesis: endogenous and exogenous carcinogens. , 2000, Mutation research.

[136]  H. Lynch,et al.  Cancer risk in mismatch repair gene mutation carriers , 2004, Familial Cancer.

[137]  M. Lavin,et al.  Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer , 2008, Nature Reviews Molecular Cell Biology.

[138]  M. Katsuki,et al.  Most tumors in transgenic mice with human c-Ha-ras gene contained somatically activated transgenes. , 1990, Oncogene.

[139]  Yanjue Wu,et al.  Transgenic C. elegans as a model in Alzheimer's research. , 2005, Current Alzheimer research.

[140]  X. Cui,et al.  Targeted integration in rat and mouse embryos with zinc-finger nucleases , 2011, Nature Biotechnology.

[141]  R. Jaenisch Transgenic animals. , 1988, Science.

[142]  K. Korach,et al.  Increased blood pressure in mice lacking cytochrome P450 2J5 , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[143]  J. Peters,et al.  Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643. , 1997, Carcinogenesis.

[144]  P. Leder,et al.  Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: Synergistic action of oncogenes in vivo , 1987, Cell.

[145]  P. Apostoli,et al.  Whole body action of xenoestrogens with different chemical structures in estrogen reporter male mice. , 2004, Toxicology.

[146]  J. Ward,et al.  Neonatal lethality associated with respiratory distress in mice lacking cytochrome P450 1A2. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[147]  H. Frucht,et al.  The Genetics of Colorectal Cancer , 2002, Annals of Internal Medicine.

[148]  R. Schulte‐Hermann,et al.  Testing for induction of DNA synthesis in human hepatocyte primary cultures by rat liver tumor promoters. , 1991, Cancer research.

[149]  D. Nebert,et al.  Differential metabolism of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in mice humanized for CYP1A1 and CYP1A2. , 2005, Chemical research in toxicology.

[150]  M. Capecchi,et al.  Altering the genome by homologous recombination. , 1989, Science.

[151]  R. Maronpot,et al.  The Orphan Nuclear Receptor Constitutive Active/Androstane Receptor Is Essential for Liver Tumor Promotion by Phenobarbital in Mice , 2004, Cancer Research.

[152]  R. Tennant,et al.  Responses of transgenic mouse lines p53(+/-) and Tg.AC to agents tested in conventional carcinogenicity bioassays. , 2000, Toxicological sciences : an official journal of the Society of Toxicology.

[153]  G. Lucignani,et al.  Techniques: reporter mice - a new way to look at drug action. , 2004, Trends in pharmacological sciences.

[154]  M. Waterman,et al.  Salt-sensitive hypertension is associated with dysfunctional Cyp4a10 gene and kidney epithelial sodium channel. , 2006, The Journal of clinical investigation.

[155]  R. Jaenisch,et al.  Simian virus 40 DNA sequences in DNA of healthy adult mice derived from preimplantation blastocysts injected with viral DNA. , 1974, Proceedings of the National Academy of Sciences of the United States of America.

[156]  R. Tennant,et al.  Evaluation of transgenic mouse bioassays for identifying carcinogens and noncarcinogens. , 1996, Mutation research.

[157]  F. Gonzalez,et al.  Humanized Mouse Lines and Their Application for Prediction of Human Drug Metabolism and Toxicological Risk Assessment , 2008, Journal of Pharmacology and Experimental Therapeutics.

[158]  S. Teichberg,et al.  The effects of phenobarbital and diphenylhydantoin on liver function and morphology. , 1980, The Journal of pediatrics.

[159]  J. Lehmann,et al.  The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. , 1998, The Journal of clinical investigation.

[160]  T. Shimada,et al.  Activation of procarcinogens by human cytochrome P450 enzymes. , 1998, Mutation research.

[161]  F. Gonzalez,et al.  The PPAR alpha-humanized mouse: a model to investigate species differences in liver toxicity mediated by PPAR alpha. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[162]  I. Lambert,et al.  Detailed review of transgenic rodent mutation assays. , 2005, Mutation research.

[163]  C. Wolf,et al.  Increased skin tumorigenesis in mice lacking pi class glutathione S-transferases. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[164]  Christopher A Bradfield,et al.  The search for endogenous activators of the aryl hydrocarbon receptor. , 2008, Chemical research in toxicology.

[165]  B. Lake,et al.  Effect of chronic phenobarbitone administration on liver tumour formation in the C57BL/10J mouse. , 2009, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[166]  R. Feil,et al.  Inducible Cre mice. , 2009, Methods in molecular biology.

[167]  I. M. Jones,et al.  A method to quantify spontaneous and in vivo induced thioguanine-resistant mouse lymphocytes. , 1985, Mutation research.

[168]  J. Lehmann,et al.  Diverse roles of the nuclear orphan receptor CAR in regulating hepatic genes in response to phenobarbital. , 2002, Molecular pharmacology.

[169]  K. Kolaja,et al.  Reversibility of promoter induced hepatic focal lesion growth in mice. , 1996, Carcinogenesis.

[170]  X. Sun,et al.  Targeted disruption of the mouse estrogen sulfotransferase gene reveals a role of estrogen metabolism in intracrine and paracrine estrogen regulation. , 2001, Endocrinology.

[171]  O. Ueda,et al.  Mutagenicity of 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine (PhIP) in the new gpt delta transgenic mouse. , 1999, Cancer letters.

[172]  J. Manson,et al.  Transgenic models of the transmissible spongiform encephalopathies , 2001, Expert Reviews in Molecular Medicine.

[173]  L. Tesson,et al.  Transgenesis in rats: Technical aspects and models , 1996, Transgenic Research.

[174]  L. Donehower,et al.  Is p53 Haploinsufficient for Tumor Suppression? Implications for the p53+/- Mouse Model in Carcinogenicity Testing , 2001, Toxicologic pathology.

[175]  J. Short,et al.  Development of a short-term, in vivo mutagenesis assay: the effects of methylation on the recovery of a lambda phage shuttle vector from transgenic mice. , 1990, Nucleic acids research.

[176]  H. van Steeg,et al.  DNA Repair—Deficient Xpa and Xpa/p53+/- Knock-Out Mice: Nature of the Models , 2001, Toxicologic pathology.

[177]  J. Beijnen,et al.  Inhibition and Stimulation of Intestinal and Hepatic CYP3A Activity: Studies in Humanized CYP3A4 Transgenic Mice Using Triazolam , 2009, Drug Metabolism and Disposition.

[178]  J. Ward,et al.  Cytochrome P450 CYP1B1 determines susceptibility to 7, 12-dimethylbenz[a]anthracene-induced lymphomas. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[179]  S. Cohen,et al.  Alternative Models for Carcinogenicity Testing: Weight of Evidence Evaluations Across Models , 2001, Toxicologic pathology.

[180]  R. Jaenisch Germ line integration and Mendelian transmission of the exogenous Moloney leukemia virus. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[181]  T. Kodama,et al.  Therapeutic Role of Rifaximin in Inflammatory Bowel Disease: Clinical Implication of Human Pregnane X Receptor Activation , 2010, Journal of Pharmacology and Experimental Therapeutics.

[182]  B. Komm,et al.  An innovative method to classify SERMs based on the dynamics of estrogen receptor transcriptional activity in living animals. , 2010, Molecular endocrinology.

[183]  D. Davidson,et al.  The CF mouse: an important tool for studying cystic fibrosis , 2001, Expert Reviews in Molecular Medicine.

[184]  R. Cardiff,et al.  v-Ha-ras transgene abrogates the initiation step in mouse skin tumorigenesis: effects of phorbol esters and retinoic acid. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[185]  D. Nebert,et al.  Theophylline pharmacokinetics: comparison of Cyp1a1(−/−) and Cyp1a2(−/−) knockout mice, humanized hCYP1A1_1A2 knock-in mice lacking either the mouse Cyp1a1 or Cyp1a2 gene, and Cyp1(+/+) wild-type mice , 2005, Pharmacogenetics and genomics.

[186]  F. Gonzalez,et al.  Expression of the human CYP3A4 gene in the small intestine of transgenic mice: in vitro metabolism and pharmacokinetics of midazolam. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[187]  D. Lowy,et al.  Function and regulation of ras. , 1993, Annual review of biochemistry.

[188]  L. Liaw,et al.  Targeted Genome Modification in Mice Using Zinc-Finger Nucleases , 2010, Genetics.

[189]  A. Maggi,et al.  Differential effect of pure isoflavones and soymilk on estrogen receptor activity in mice. , 2009, Toxicology and applied pharmacology.

[190]  Takayoshi Suzuki,et al.  In vivo transgenic mutation assays. , 2003, Mutation research.

[191]  T. Pineau,et al.  Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators , 1995, Molecular and cellular biology.

[192]  C. Wolf,et al.  In Vivo Responses of the Human and Murine Pregnane X Receptor to Dexamethasone in Mice , 2010, Drug Metabolism and Disposition.

[193]  D. Moore,et al.  The nuclear receptor CAR mediates specific xenobiotic induction of drug metabolism , 2000, Nature.

[194]  Xiaochao Ma,et al.  The pregnane X receptor: from bench to bedside. , 2008, Expert opinion on drug metabolism & toxicology.

[195]  M. Dickins Induction of cytochromes P450. , 2004, Current topics in medicinal chemistry.

[196]  S. Dertinger,et al.  The in vivo pig‐a gene mutation assay, a potential tool for regulatory safety assessment , 2010, Environmental and molecular mutagenesis.

[197]  P. Peltomäki,et al.  The genetics of HNPCC: application to diagnosis and screening. , 2006, Critical reviews in oncology/hematology.

[198]  J. Lehmann,et al.  An Orphan Nuclear Receptor Activated by Pregnanes Defines a Novel Steroid Signaling Pathway , 1998, Cell.

[199]  M. De Felici,et al.  Genistein is an efficient estrogen in the whole-body throughout mouse development. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[200]  I. Mangelsdorf,et al.  TRANSGENIC ANIMAL MUTAGENICITY ASSAYS , 2006 .

[201]  J. Bailar,et al.  Toxicity Testing in the 21st Century: A Vision and a Strategy , 2010, Journal of toxicology and environmental health. Part B, Critical reviews.

[202]  D. Nebert,et al.  Targeted knockout of Cyp1a1 gene does not alter hepatic constitutive expression of other genes in the mouse [Ah] battery. , 2000, Biochemical and biophysical research communications.

[203]  Rudolf B. Beems,et al.  Xpa and Xpa/p53+/- Knockout Mice: Overview of Available Data , 2001, Toxicologic pathology.

[204]  D. Moore,et al.  Xenobiotic stress induces hepatomegaly and liver tumors via the nuclear receptor constitutive androstane receptor. , 2005, Molecular endocrinology.

[205]  G. Perdew,et al.  Use of 2-azido-3-[125I]iodo-7,8-dibromodibenzo-p-dioxin as a probe to determine the relative ligand affinity of human versus mouse aryl hydrocarbon receptor in cultured cells. , 2004, Molecular pharmacology.

[206]  C. Hsieh,et al.  Germline Competent Embryonic Stem Cells Derived from Rat Blastocysts , 2008, Cell.

[207]  O. Ueda,et al.  Other transgenic mutation assays: A new transgenic mouse mutagenesis test system using Spi− and 6‐thioguanine selections , 1996, Environmental and molecular mutagenesis.

[208]  D W Nebert,et al.  Cyp1a2(-/-) null mutant mice develop normally but show deficient drug metabolism. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[209]  R. Tennant,et al.  Use of transgenic animals for carcinogenicity testing: considerations and implications for risk assessment. , 2000, Toxicologic pathology.